Pemphigus vulgaris. Pemphigus vulgaris
Conditions
Interventions
rituximab 500 mg intravenously weekly for 4 weeks in each cycle.
Treatment - Drugs
rituximab 500 mg intravenously weekly for 4 weeks in each cycle
Sponsors
Vice-chancellor for Research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with Pemphigus Vulgaris who are candidates for rituximab (failure to respond or frequent recurrences under long-term (months to years) oral corticosteroids more than 10 mg daily with or without additional immunosuppressive therapy? or oral corticosteroids intolerance with or without short and long-term oral coricosteroids side effects) Exclusion criterion were: pregnancy and breast feeding?history of sensitization to murine protein?hepatitis B cariers?cardiac arrhythmias & angina pectoris?high tumor burden?active infections
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic effect(new blisters per day, Nikolsky’s sign and epithelialization over the denuded surfaces). Timepoint: weekly for 1 month and then monthly after injecting rituximab. Method of measurement: clinical examination.;The dose of oral prednisolone. Timepoint: prior to treatment, next 3 months, next 6 months and the final in the last visit. Method of measurement: mg per day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: weekly for 1 month and then monthly after injecting rituximab. Method of measurement: clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomayeh Khezri
Tehran University of Medical Sciences
Outcome results
None listed